Aura Biosciences 미래 성장

Future 기준 확인 0/6

Aura Biosciences 의 수익은 연간 8.9% 감소할 것으로 예상되는 반면, 연간 수익은 78.3% 로 증가할 것으로 예상됩니다. 78.3% 연간. EPS는 연간 5.5% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-8.9%

수익 성장률

-5.5%

EPS 성장률

Biotechs 수익 성장	28.4%
매출 성장률	78.3%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	14 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10

수익 및 매출 성장 예측

NasdaqGM:AURA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-120	-156	-106	5
12/31/2025	N/A	-100	-109	-85	7
12/31/2024	N/A	-83	-81	-77	7
9/30/2024	N/A	-83	-75	-73	N/A
6/30/2024	N/A	-81	-74	-73	N/A
3/31/2024	N/A	-79	-73	-72	N/A
12/31/2023	N/A	-76	-65	-64	N/A
9/30/2023	N/A	-71	-65	-64	N/A
6/30/2023	N/A	-68	-61	-60	N/A
3/31/2023	N/A	-63	-56	-56	N/A
12/31/2022	N/A	-59	-56	-55	N/A
9/30/2022	N/A	-55	-50	-49	N/A
6/30/2022	N/A	-52	-49	-47	N/A
3/31/2022	N/A	-51	-45	-42	N/A
12/31/2021	N/A	-46	-35	-32	N/A
9/30/2021	N/A	-40	-26	-24	N/A
6/30/2021	N/A	-33	-23	-22	N/A
3/31/2021	N/A	-29	-22	-21	N/A
12/31/2020	N/A	-30	-25	-24	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AURA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: AURA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: AURA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: AURA 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: AURA 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AURA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Aura Biosciences 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Aura Biosciences, Inc. Announces Positive Early Data from an Ongoing Phase 1 Clinical Trial of Bel-sar (AU-011) in Patients with NMIBC

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences, Inc. Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as A First- Line Treatment for Early-Stage Choroidal Melanoma

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Insider selling

Founder recently sold US$121k worth of stock

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Independent Chairman of the Board recently bought US$1.4m worth of stock

Founder notifies of intention to sell stock

Aura Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $99 million.

Aura Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Founder recently sold US$65k worth of stock

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Independent Chairman of the Board recently bought US$168k worth of stock

Aura Biosciences, Inc. Announces Executive Changes

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting

Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Value Index

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AUu-011) Versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences Present Updates Belzupacap Sarotalocan (Au-011) Data on Multiple Studies At the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Independent Chairman of the Board recently bought US$716k worth of stock

Aura Biosciences, Inc. Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences, Inc. Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견